221 related articles for article (PubMed ID: 24726617)
1. Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.
Papadopoulou LC; Kyriazou AV; Bonovolias ID; Tsiftsoglou AS
Blood Cells Mol Dis; 2014; 53(1-2):84-90. PubMed ID: 24726617
[TBL] [Abstract][Full Text] [Related]
2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
3. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
[TBL] [Abstract][Full Text] [Related]
5. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
6. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
7. Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Bonovolias ID; Tsiftsoglou AS
Oncol Res; 2009; 17(11-12):535-47. PubMed ID: 19806784
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
9. Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
Karimiani EG; Marriage F; Merritt AJ; Burthem J; Byers RJ; Day PJ
Exp Hematol; 2014 Mar; 42(3):183-191.e5. PubMed ID: 24269846
[TBL] [Abstract][Full Text] [Related]
10. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Dasmahapatra G; Patel H; Nguyen T; Attkisson E; Grant S
Clin Cancer Res; 2013 Jan; 19(2):404-14. PubMed ID: 23204129
[TBL] [Abstract][Full Text] [Related]
11. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
12. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
13. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
14. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
16. Roots of imatinib resistance: a question of self-renewal?
Burchert A
Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of imatinib-induced apoptosis of BCR/ABL-expressing cells by nutlin-3 through synergistic activation of the mitochondrial apoptotic pathway.
Kurosu T; Wu N; Oshikawa G; Kagechika H; Miura O
Apoptosis; 2010 May; 15(5):608-20. PubMed ID: 20094798
[TBL] [Abstract][Full Text] [Related]
18. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
[TBL] [Abstract][Full Text] [Related]
20. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Morinaga K; Yamauchi T; Kimura S; Maekawa T; Ueda T
Int J Cancer; 2008 Jun; 122(11):2621-7. PubMed ID: 18338755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
